VivoSeq
Oncology

Kidney Cancer

197

Pipeline Programs↗

28

Active Trials↗

65

Companies Involved↗

Kidney Cancer is a highly competitive landscape with 197 programs across 65 companies. The most active players are Lisata Therapeutics, Inc., BioMedicines, Teva. 9 therapies are approved with 23 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

80/100

Pipeline Velocity

27/100

Mech. Concentration

6/100

Completion Rate

73/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

L

Lisata Therapeutics, Inc.

2 programs

Phase 1B

BioMedicines

1 program

Phase 1Teva logo

Teva

1 program

Phase 1Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 1Sanofi logo

Sanofi

5 programs

Phase 2Takeda logo

Takeda

3 programs

Phase 2

Pipeline

Programs by Phase

Preclinical6

Kisplyx

Novartis

Therapeutic Allogeneic Lymphocytes

Eastern Cooperative Oncology Group

Blood Collection

Assistance Publique - Hôpitaux de Paris

Antiangiogenesis Therapy

National Cancer Institute, France

VEGF-TKI

City of Hope Medical Center

Phase 127

Paclitaxel

Teva

Mrna-1651

Moderna

Tremelimumab

AstraZeneca

Carboplatin

Avyxa

Temsirolimus

Prism Pharmaceuticals

Phase 2132

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Vandetanib

Genzyme, a Sanofi Company

Antineoplaston A10

Burzynski Research Institute

Alvocidib

Sumitomo Pharma America, Inc.

Atezolizumab

Roche

Phase 323

Aldesleukin

Iovance Biotherapeutics, Inc.

Dactinomycin

RECORDATI GROUP

Belzutifan

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Cyclophosphamide

Baxter Healthcare Corporation

Thalidomide

Bristol-Myers Squibb

Approved9

Acarbose

Bayer

Ibuprofen

Kenvue Brands

Acetaminophen

Kenvue Brands

Mannitol

B. Braun Medical Inc.

Capmatinib

Novartis

Analysis

Modality Breakdown

82%

Small molecule

157 of 191 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody158%Protein / enzyme95%Vaccine53%Cell therapy32%RNA therapy1<1%Radiopharmaceutical1<1%

Small molecule leads; the ring shows all 191 classified programs, each share of the total. Modality classified for 99% of 217 pipeline programs.

Analysis

Trial Status

270

clinical trials

Completed159 · 59%
Terminated44 · 16%
Unknown status23 · 9%
Withdrawn14 · 5%
Active, not recruiting13 · 5%
Recruiting11 · 4%
Other6 · 2%

Clinical Trials

Trial Activity

270 trials

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
Recruiting·—·Phase 2·NCT04322955·48 enrolled
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT06601296·15 enrolled
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT06447103·91 enrolled
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
Recruiting·SSun Yat-sen University·Phase 3·NCT06726421·252 enrolled
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Recruiting·VVanderbilt-Ingram Cancer Center·Phase 2·NCT05361720·54 enrolled
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Recruiting·OOsel, Inc.·Phase 1·NCT06399419·28 enrolled
CD70-targeted immunoPET Imaging of Kidney Cancer
Recruiting·RRenJi Hospital·Phase 2·NCT06680089·300 enrolled
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Recruiting·SWOG Cancer Research Network·Phase 3·NCT04510597·364 enrolled
REMEDY-RCC: Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma - A Prospective, Exploratory, Single-Center Study
Recruiting·JJinling Hospital, China·Phase 2·NCT07611825·33 enrolled
Protective Effect of Perioperative Ursodeoxycholic Acid Intervention Against Ischemia-Reperfusion Injury During Partial Nephrectomy: A Single-Center, Prospective, Double-Blind, Randomized Controlled Trial (PURIFY Trial)
Recruiting·JJinling Hospital, China·Phase 2·NCT07672860·146 enrolled
UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)
Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT03293563·30,000 enrolled
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05239533·9 enrolled
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03587662·30 enrolled
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT05411081·200 enrolled
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
Active, not recruiting·—·Phase 1·NCT05122546·31 enrolled
Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)